12 Month Price Forecast For QNCX
Distance to QNCX Price Forecasts
QNCX Price Momentum
๐ค Considering Quince Therapeutics (QNCX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 6:09 AM UTC
QNCX Analyst Ratings & Price Targets
Based on our analysis of 4 Wall Street analysts, QNCX has a consensus that is bullish. The median price target is $9.00, with forecasts ranging from $6.00 to $12.00. Currently, there are 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With QNCX currently trading at $1.67, the median price forecast suggests a 438.9% upside. The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 618.6% upside, while Jason McCarthy at Maxim Group provides the most conservative target, suggesting a 259.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QNCX Analyst Consensus
QNCX Price Target Range
Latest QNCX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QNCX.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 5, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $12.00 |
Jan 2, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $12.00 |
Dec 18, 2024 | Brookline Capital | Buy | Initiates | $0.00 | |
Nov 14, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $12.00 |
Nov 12, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $12.00 |
Nov 7, 2024 | Maxim Group | Jason McCarthy | Buy | Initiates | $6.00 |
Oct 29, 2024 | Rodman & Renshaw | Elemer Piros | Buy | Initiates | $11.00 |
Oct 22, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $12.00 |
May 11, 2022 | Credit Suisse | Underperform | Maintains | $0.00 | |
Mar 9, 2022 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
Jan 28, 2022 | Canaccord Genuity | Hold | Downgrade | $0.00 | |
Jan 27, 2022 | JMP Securities | Market Perform | Downgrade | $0.00 | |
Oct 27, 2021 | B of A Securities | Underperform | Downgrade | $0.00 | |
Oct 27, 2021 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
Sep 16, 2021 | Canaccord Genuity | Buy | Maintains | $0.00 | |
Aug 26, 2021 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
Feb 17, 2021 | Jefferies | Hold | Downgrade | $0.00 | |
Dec 11, 2020 | Citigroup | Sell | Initiates | $0.00 | |
Dec 7, 2020 | B of A Securities | Buy | Upgrade | $0.00 | |
Jun 24, 2020 | HC Wainwright & Co. | Buy | Initiates | $0.00 |
Stocks Similar to Quince Therapeutics, Inc.
The following stocks are similar to Quince Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Quince Therapeutics, Inc. (QNCX) Financial Data
Quince Therapeutics, Inc. has a market capitalization of $73.48M with a P/E ratio of -2.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -79.4%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Quince Therapeutics, Inc. (QNCX) Company Overview
About Quince Therapeutics, Inc.
Develops therapeutics for rare diseases.
Quince Therapeutics operates as a biopharmaceutical company focused on acquiring and commercializing innovative therapeutics for rare and debilitating diseases. The company generates revenue through the development and potential commercialization of its lead asset, EryDex, which targets rare pediatric neurodegenerative disorders. Additionally, their AIDE technology platform offers a unique drug/device combination that enhances treatment efficacy, potentially leading to lucrative market opportunities.
Founded in 2012 and headquartered in South San Francisco, California, Quince Therapeutics was previously known as Cortexyme, Inc. The company's focus on rare diseases aligns with increasing investor interest in specialized therapeutics, which may provide a competitive edge in a niche market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
32
CEO
Dr. Dirk Thye M.D.
Country
United States
IPO Year
2019
Website
www.quincetx.comQuince Therapeutics, Inc. (QNCX) Latest News & Analysis
Quince Therapeutics (Nasdaq: QNCX) published safety data for EryDex, used in treating Ataxia-Telangiectasia, in Frontiers in Neurology, highlighting its potential for addressing unmet medical needs.
Safety data publication for EryDex in treating Ataxia-Telangiectasia could signal progress for Quince Therapeutics, potentially increasing investor confidence and stock value.
Quince Therapeutics (Nasdaq: QNCX) will host an investor webinar on February 7, 2025, to discuss its treatment for the rare pediatric disease Ataxia-Telangiectasia.
Quince Therapeutics' webinar highlights its focus on a rare disease, potentially attracting investor interest in its innovative treatments and future growth prospects.
Quince Therapeutics (Nasdaq: QNCX) appointed Dr. William Whitehouse as a new board member. He is an Honorary Clinical Associate Professor and former Consultant Paediatric Neurologist.
The appointment of Dr. Whitehouse enhances Quince Therapeutics' credibility and expertise in rare disease treatment, potentially boosting investor confidence and stock performance.
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
2 months agoQuince Therapeutics (Nasdaq: QNCX) reported Q3 2024 financial results and updates on its development pipeline, noting accelerating enrollment in clinical trials.
Quince Therapeutics' pipeline update and financial results signal progress in rare disease treatments, potentially enhancing investor confidence and impacting stock performance.
Quince Therapeutics (Nasdaq: QNCX) presented safety data from its Phase 3 ATTeST trial at the CNS Annual Meeting, focusing on treatments for rare diseases.
Quince Therapeutics' presentation of safety data from its Phase 3 trial could influence investor confidence and stock performance, signaling progress in addressing rare diseases.
Quince Therapeutics (Nasdaq: QNCX) presented data from its Phase 3 ATTeST trial for EryDex at the 2024 International Congress for Ataxia Research, focusing on treatments for rare diseases.
Quince Therapeutics' presentation at a major conference highlights progress in their Phase 3 clinical trial, potentially boosting investor confidence in their lead asset and future growth.
Frequently Asked Questions About QNCX Stock
What is Quince Therapeutics, Inc.'s (QNCX) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Quince Therapeutics, Inc. (QNCX) has a median price target of $9.00. The highest price target is $12.00 and the lowest is $6.00.
Is QNCX stock a good investment in 2025?
According to current analyst ratings, QNCX has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for QNCX stock?
Wall Street analysts predict QNCX stock could reach $9.00 in the next 12 months. This represents a 438.9% increase from the current price of $1.67. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Quince Therapeutics, Inc.'s business model?
Quince Therapeutics operates as a biopharmaceutical company focused on acquiring and commercializing innovative therapeutics for rare and debilitating diseases. The company generates revenue through the development and potential commercialization of its lead asset, EryDex, which targets rare pediatric neurodegenerative disorders. Additionally, their AIDE technology platform offers a unique drug/device combination that enhances treatment efficacy, potentially leading to lucrative market opportunities.
What is the highest forecasted price for QNCX Quince Therapeutics, Inc.?
The highest price target for QNCX is $12.00 from Jason Kolbert at D. Boral Capital, which represents a 618.6% increase from the current price of $1.67.
What is the lowest forecasted price for QNCX Quince Therapeutics, Inc.?
The lowest price target for QNCX is $6.00 from Jason McCarthy at Maxim Group, which represents a 259.3% increase from the current price of $1.67.
What is the overall QNCX consensus from analysts for Quince Therapeutics, Inc.?
The overall analyst consensus for QNCX is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are QNCX stock price projections?
Stock price projections, including those for Quince Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.